Oragenics Inc (OGEN)
0.397
0.00 (0.00%)
USD |
NYAM |
Sep 27, 16:00
0.395
0.00 (0.00%)
After-Hours: 20:00
Oragenics SG&A Expense (Annual): 5.452M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.452M |
| December 31, 2022 | 4.480M |
| December 31, 2021 | 5.272M |
| December 31, 2020 | 4.534M |
| December 31, 2019 | 3.757M |
| December 31, 2018 | 4.022M |
| December 31, 2017 | 3.179M |
| December 31, 2016 | 3.788M |
| December 31, 2015 | 3.047M |
| December 31, 2014 | 3.322M |
| December 31, 2013 | 7.540M |
| Date | Value |
|---|---|
| December 31, 2012 | 5.025M |
| December 31, 2011 | 5.628M |
| December 31, 2010 | 6.285M |
| December 31, 2009 | 4.918M |
| December 31, 2008 | 4.312M |
| December 31, 2007 | 0.9027M |
| December 31, 2006 | 1.004M |
| December 31, 2005 | 1.167M |
| December 31, 2004 | 1.33M |
| December 31, 2003 | 0.7386M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
3.757M
Minimum
2019
5.452M
Maximum
2023
4.699M
Average
4.534M
Median
2020
SG&A Expense (Annual) Benchmarks
| Shuttle Pharmaceuticals Holdings Inc | 2.375M |
| Perspective Therapeutics Inc | 21.06M |
| Alaunos Therapeutics Inc | 12.22M |
| Cocrystal Pharma Inc | 5.99M |
| Cara Therapeutics Inc | 27.65M |